Small flu vax players poised to win 'sizable' share of market, firm predicts
06 December 2016
As new flu vaccine technology emerges in the coming years, smaller players will have a shot at stealing market share from the world leaders who have for years had a hold on the market.
EU health regulator warns some hep C drugs could reactivate hep B
05 December 2016
The European Medicines Agency warned on Friday that some of the most successful hepatitis C treatments on the market could reactivate hepatitis B in patients, the second time this year it has raised safety concerns over these treatments.
Influenza vaccine ‘desperately’ needs improvement
05 December 2016
The current seasonal influenza vaccine is not perfect, but experts agree that it remains the best available tool for fighting influenza — at least for now.
Pharma executives weigh in on possible changes under Trump
02 December 2016
Top executives from large U.S. drugmakers on Thursday discussed for the first time possible changes for the industry under President-elect Donald Trump, and issues that have damaged the reputation of their industry.
Biotech’s biggest protesters are turning into its supporters
02 December 2016
For decades the biotech industry has been hounded by activists over animal testing. Most notably, a campaign against Huntington Life Sciences in the late 1990s through 2000s included arson, harassment, threats and alleged fire bombings. Less severe, but still troubling for biotech, animal rights activists join with anti-GMOers most years to protest at the Biotechnology Innovation Organization (BIO) convention.
Immunization Administration and the Future of Pharmacy
01 December 2016
CDC officials report that more than 25% of influenza vaccines are administered by pharmacists. It would be safe to say that the immunization role of pharmacists has become an important public health success. The American Pharmacists Association (APhA) has more than 300,000 pharmacists trained as immunizers.
Pfizer Expands Humanitarian Assistance Program
01 December 2016
In a Nov. 11, 2016 press release Pfizer said that the company will be expanding its humanitarian assistance program allowing for broader access to the Prevenar 13 vaccine in humanitarian emergency settings. In situations where there is a need for humanitarian aid, Prevenar 13, a pneumococcal conjugate vaccine, will now be offered in a multi-dose vial for $3.10 per dose. During the first year of the expanded program, Pfizer said it will be donating all sales proceeds to humanitarian groups.
01 December 2016
Ferring Pharmaceuticals and Aché Laboratórios Farmacêuticos today announced a long-term collaboration aimed at improving the bioavailability, efficacy and safety profile of oral therapeutic medicines through nanotechnology. Potential benefits of research in this area include a reduction of adverse effects, increased patient adherence to treatment and more convenient dosing.
Contract research worth £192M a year to U.K. NHS, says KPMG
01 December 2016
Carrying out contract clinical research for life science companies injects around £192 million into the U.K. National Health Service every year in income and cost-savings, says a new report.
Pfizer's Herceptin biosimilar succeeds in key breast cancer study
01 December 2016
Pfizer Inc said on Wednesday its experimental biosimilar of Roche Holding AG's blockbuster breast cancer treatment Herceptin was found comparable with the branded version in a key study.
14 March 2024
26 February 2024
NovaMedica team wishes you a Merry Christmas and a Happy New Year!
26 December 2023
Orphan drug market to reach $270B by 2028 : Evaluate
25 April 2024
Russian drug for the treatment of viral hepatitis will be exempt from duty in Mongolia
24 April 2024
PM Mishustin: “We need to increase the production of vital and essential drugs in Russia”
24 April 2024
The Future of Pharmacy: How Advancements in Technology Are Transforming the Field
23 April 2024